Rocket Pharma shares drop despite FDA approval

Rocket Pharmaceuticals experienced a significant share price decline of over 15% following the FDA's approval of its gene therapy for a rare childhood immune disorder. Investors appear to be focusing on potential challenges related to the therapy's market uptake rather than celebrating the groundbreaking regulatory milestone. This reaction highlights the market's sensitivity to commercialization hurdles and the long-term viability of new treatments, even those receiving first-of-their-kind approvals. The company now faces the task of demonstrating the therapy's real-world effectiveness and accessibility.